Literature DB >> 30687565

Chlamydia pneumoniae Infection and Inflammatory Diseases.

Rebecca A Porritt1, Timothy R Crother1.   

Abstract

Chlamydia pneumoniae, an obligate intracellular bacterial pathogen, has long been investigated as a potential developmental or exacerbating factor in various pathologies. Its unique lifestyle and ability to disseminate throughout the host while persisting in relative safety from the immune response has placed this obligate intracellular pathogen in the crosshairs as a potentially mitigating factor in chronic inflammatory diseases. Many animal model and human correlative studies have been performed to confirm or deny a role for C. pneumoniae infection in these disorders. In some cases, antibiotic clinical trials were conducted to prove a link between bacterial infections and atherosclerosis. In this review, we detail the latest information regarding the potential role that C. pneumoniae infection may have in chronic inflammatory diseases.

Entities:  

Keywords:  Alzheimer’s; Chlamydia pneumoniae; arthritis; asthma; atherosclerosis; cancer

Year:  2016        PMID: 30687565      PMCID: PMC6345537          DOI: 10.1615/ForumImmunDisTher.2017020161

Source DB:  PubMed          Journal:  For Immunopathol Dis Therap        ISSN: 2151-8017


  137 in total

1.  Chlamydia pneumoniae and asthma.

Authors:  D L Hahn
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

2.  In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations.

Authors:  H M Freidank; P Losch; H Vögele; M Wiedmann-Al-Ahmad
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

3.  Signal transduction pathways activated in endothelial cells following infection with Chlamydia pneumoniae.

Authors:  M Krüll; A C Klucken; F N Wuppermann; O Fuhrmann; C Magerl; J Seybold; S Hippenstiel; J H Hegemann; C A Jantos; N Suttorp
Journal:  J Immunol       Date:  1999-04-15       Impact factor: 5.422

4.  Asthma, atopy and Chlamydia pneumoniae antibodies in adults.

Authors:  L Von Hertzen; M Töyrylä; A Gimishanov; A Bloigu; M Leinonen; P Saikku; T Haahtela
Journal:  Clin Exp Allergy       Date:  1999-04       Impact factor: 5.018

5.  Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice.

Authors:  T C Moazed; L A Campbell; M E Rosenfeld; J T Grayston; C C Kuo
Journal:  J Infect Dis       Date:  1999-07       Impact factor: 5.226

6.  Chlamydia pneumoniae infection of human endothelial cells induces proliferation of smooth muscle cells via an endothelial cell-derived soluble factor(s).

Authors:  B K Coombes; J B Mahony
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

7.  The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae.

Authors:  H Hu; G N Pierce; G Zhong
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

8.  Role of innate and adaptive immunity in the outcome of primary infection with Chlamydia pneumoniae, as analyzed in genetically modified mice.

Authors:  M E Rottenberg; A C Gigliotti Rothfuchs; D Gigliotti; C Svanholm; L Bandholtz; H Wigzell
Journal:  J Immunol       Date:  1999-03-01       Impact factor: 5.422

9.  Chlamydia pneumoniae as a triggering infection in reactive arthritis.

Authors:  T Hannu; M Puolakkainen; M Leirisalo-Repo
Journal:  Rheumatology (Oxford)       Date:  1999-05       Impact factor: 7.580

10.  Infection of human endothelial cells with Chlamydia pneumoniae stimulates transendothelial migration of neutrophils and monocytes.

Authors:  R E Molestina; R D Miller; J A Ramirez; J T Summersgill
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

View more
  9 in total

Review 1.  Hacking the host: exploitation of macrophage polarization by intracellular bacterial pathogens.

Authors:  Joseph D Thiriot; Yazmin B Martinez-Martinez; Janice J Endsley; Alfredo G Torres
Journal:  Pathog Dis       Date:  2020-02-01       Impact factor: 3.166

2.  Opsonophagocytosis of Chlamydia pneumoniae by Human Monocytes and Neutrophils.

Authors:  Mads Lausen; Mathilde Selmar Pedersen; Nareen Sherzad Kader Rahman; Liv Therese Holm-Nielsen; Faduma Yahya Mohamed Farah; Gunna Christiansen; Svend Birkelund
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

Review 3.  Microbial Infections Are a Risk Factor for Neurodegenerative Diseases.

Authors:  Sarah K Lotz; Britanie M Blackhurst; Katie L Reagin; Kristen E Funk
Journal:  Front Cell Neurosci       Date:  2021-07-07       Impact factor: 5.505

Review 4.  Immunopathogenesis of genital Chlamydia infection: insights from mouse models.

Authors:  Jacob Dockterman; Jörn Coers
Journal:  Pathog Dis       Date:  2021-03-31       Impact factor: 3.951

5.  Autophagy Limits Inflammasome During Chlamydia pneumoniae Infection.

Authors:  Timothy R Crother; Rebecca A Porritt; Jargalsaikhan Dagvadorj; Gantsetseg Tumurkhuu; Anatoly V Slepenkin; Ellena M Peterson; Shuang Chen; Kenichi Shimada; Moshe Arditi
Journal:  Front Immunol       Date:  2019-04-12       Impact factor: 7.561

Review 6.  Chlamydia pneumoniae infections and development of lung cancer: systematic review.

Authors:  Nadeesha Madushani Premachandra; J A A Sampath Jayaweera
Journal:  Infect Agent Cancer       Date:  2022-03-22       Impact factor: 2.965

7.  Influence of Fetuin-A on Chlamydia muridarum Pulmonary Infection.

Authors:  Faria Mahjabeen; Jieh-Juen Yu; James P Chambers; Rishein Gupta; Bernard P Arulanandam
Journal:  Int J Microbiol       Date:  2022-04-19

8.  An agent-based model to investigate microbial initiation of Alzheimer's via the olfactory system.

Authors:  Shalini Sundar; Carly Battistoni; Ryan McNulty; Fernando Morales; Jonathan Gorky; Henry Foley; Prasad Dhurjati
Journal:  Theor Biol Med Model       Date:  2020-04-15       Impact factor: 2.432

Review 9.  Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance.

Authors:  Priya Veluswamy; Max Wacker; Maximilian Scherner; Jens Wippermann
Journal:  Int J Mol Sci       Date:  2020-10-31       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.